However, a larger NOM or a higher mVAF in the during-treatment cf-tDNA sample was associated with shorter PFS following TISF collection in both IDH-wild-type (NOM: hazard ratio 2.478, log-rank p = 0.0107; mVAF: hazard ratio 2.566, log-rank p = 0.0076) and IDH-mutant gliomas (NOM: hazard ratio 3.846, log-rank p = 0.0004; mVAF: hazard ratio 3.821, log-rank p = 0.0005) (Figures 4C–F). The gene discussed is IDH1; the disease is central nervous system cancer.